Figure 2.

Effects of BU10119 in adult male CD1 mice in the warm‐water tail‐withdrawal assay. The time course of the experiments is indicated, and tail‐withdrawal latencies are expressed as %MPE. (A) Antinociceptive effects of buprenorphine (1 mg·kg⁻¹) and BU10119 (0.3, 1 and 3 mg·kg⁻¹). *P < 0.05 as compared between buprenorphine and all other groups. (B) Antinociceptive effects of the κ‐agonist U50,488 (10 mg·kg⁻¹) were blocked by BU10119 (1 and 3 mg·kg⁻¹) and by norBNI (1 mg·kg⁻¹). *P < 0.05 as compared to BU10119 (1 and 3 mg·kg⁻¹) and norBNI (1 mg·kg⁻¹), #P < 0.05 as compared between all groups and norBNI (1 mg·kg⁻¹). (C) Antinociceptive effects of buprenorphine and morphine at 60 min post‐administration were blocked by BU10119 (1 mg·kg⁻¹) and by the irreversible μ‐antagonist CCAM (3 mg·kg⁻¹). *P < 0.05 compared to buprenorphine; #P < 0.05 compared to morphine. All values are mean ± SEM, n = 5 per group, separate experimental groups in each figure.